Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Recurrent Low-Grade Astrocytomas
NCT01338857Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Apr 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in astrocytoma, optic pathway glioma (OPG), sponsored by NYU Langone Health. Started Apr 2011; status: terminated.
02
Drugs
sorafenib
03
Conditions
astrocytomaoptic pathway glioma (OPG)
Beyond the preview
Go deeper on NCT01338857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01338857.